Detalhe da pesquisa
1.
Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
Int J Cancer
; 154(11): 1967-1978, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38329180
2.
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry.
Eur Respir J
; 61(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36180086
3.
Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
BMC Cancer
; 19(1): 108, 2019 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30700254
4.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med
; 373(2): 123-35, 2015 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26028407
5.
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
BMC Cancer
; 18(1): 135, 2018 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29402243
6.
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
Lancet Oncol
; 16(4): 447-56, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25800891
7.
Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements.
Curr Opin Oncol
; 26(2): 171-81, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24441503
8.
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Invest New Drugs
; 32(1): 123-34, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23579358
9.
Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.
Future Oncol
; 10(5): 823-33, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24799063
10.
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer.
J Thorac Oncol
; 19(5): 786-802, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38320664
11.
Long-Term Survival in Patients with Oligometastatic Non-Small Cell Lung Cancer by a Multimodality Treatment-Comparison with Stage III Disease.
Cancers (Basel)
; 16(6)2024 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539510
12.
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
JTO Clin Res Rep
; 5(4): 100626, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38586301
13.
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Lancet Oncol
; 13(1): 33-42, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22056021
14.
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study.
J Nucl Med
; 64(10): 1540-1549, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37474272
15.
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours.
Invest New Drugs
; 30(5): 1962-71, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21989836
16.
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Lancet Oncol
; 12(1): 30-7, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21169060
17.
Long-term survival of patients with central or > 7 cm T4 N0/1 M0 non-small-cell lung cancer treated with definitive concurrent radiochemotherapy in comparison to trimodality treatment.
Radiat Oncol
; 17(1): 126, 2022 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35842712
18.
Prediction of malignant lymph nodes in NSCLC by machine-learning classifiers using EBUS-TBNA and PET/CT.
Sci Rep
; 12(1): 17511, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36266403
19.
Multimodal treatment of non-small-cell lung cancer.
Lancet
; 386(9998): 1018-20, 2015 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26275734
20.
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Lancet Oncol
; 11(7): 619-26, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20570559